Translating biomarkers to clinical practice

被引:100
作者
Perlis, R. H. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Dept Psychiat, Lab Psychiat Pharmacogen, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
关键词
biomarker; test; diagnostic; genetic; cost-effectiveness; utility; STAR-ASTERISK-D; DEXAMETHASONE SUPPRESSION TEST; COST-EFFECTIVENESS ANALYSIS; SERVICES TASK-FORCE; BREAST-CANCER; ANTIDEPRESSANT RESPONSE; PREDICTION MODELS; BIPOLAR DISORDER; ROC CURVE; STEP-BD;
D O I
10.1038/mp.2011.63
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Biomarkers are the measurable characteristics of an individual that may represent risk factors for a disease or outcome, or that may be indicators of disease progression or of treatment-associated changes. In general, the process by which biomarkers, once identified, might be translated into clinical practice has received scant attention in recent psychiatric literature. A body of work in diagnostic development suggests a framework for evaluating and validating novel biomarkers, but this work may be unfamiliar to clinical and translational researchers in psychiatry. Therefore, this review focuses on the steps that might follow the identification of putative biomarkers. It first addresses standard approaches to characterizing biomarker performance, followed by demonstrations of how a putative biomarker might be shown to have clinical relevance. Finally, it addresses ways in which a biomarker-based test might be validated for clinical application in terms of efficacy and cost-effectiveness. Molecular Psychiatry (2011) 16, 1076-1087; doi:10.1038/mp.2011.63; published online 28 June 2011
引用
收藏
页码:1076 / 1087
页数:12
相关论文
共 65 条
[1]  
[Anonymous], 2010, TABLE VALID GENOMIC
[2]  
[Anonymous], INTRO COST EFFECTIVE
[3]  
ARANA GW, 1985, ARCH GEN PSYCHIAT, V42, P1193
[4]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[5]   THE MODERATOR MEDIATOR VARIABLE DISTINCTION IN SOCIAL PSYCHOLOGICAL-RESEARCH - CONCEPTUAL, STRATEGIC, AND STATISTICAL CONSIDERATIONS [J].
BARON, RM ;
KENNY, DA .
JOURNAL OF PERSONALITY AND SOCIAL PSYCHOLOGY, 1986, 51 (06) :1173-1182
[6]   Clinically responsible genetic testing in neuropsychiatric patients: A bridge too far and too soon [J].
Braff, David L. ;
Freedman, Robert .
AMERICAN JOURNAL OF PSYCHIATRY, 2008, 165 (08) :952-955
[7]   A marker for Stevens-Johnson syndrome [J].
Chung, WH ;
Hung, SI ;
Hong, HS ;
Hsih, MS ;
Yang, LC ;
Ho, HC ;
Wu, JY ;
Chen, YT .
NATURE, 2004, 428 (6982) :486-486
[8]   Statistical evaluation of prognostic versus diagnostic models: Beyond the ROC curve [J].
Cook, Nancy R. .
CLINICAL CHEMISTRY, 2008, 54 (01) :17-23
[9]   Use and misuse of the receiver operating characteristic curve in risk prediction [J].
Cook, Nancy R. .
CIRCULATION, 2007, 115 (07) :928-935
[10]   Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review [J].
Daban, Claire ;
Martinez-Aran, Anabel ;
Cruz, Nuria ;
Vieta, Eduard .
JOURNAL OF AFFECTIVE DISORDERS, 2008, 110 (1-2) :1-15